A Molecular Perspective of Clinical Benefit: Why Shouldn’t Luminal a Breast Cancer Patients be Considered in Pathological Complete Response Discussions_Crimson Publishers

A Molecular Perspective of Clinical Benefit: Why Shouldn’t Luminal a Breast Cancer Patients be Considered in Pathological Complete Response Discussions by Kieber Emmons T in Journal of Cancer Research

 

Crimson Publishers_ Novel Approaches in Cancer Study

Breast cancer is a heterogeneous disease with biological subtypes having different prognostic impacts. This facet is particularly evident in Neoadjuvant trials where Pathological Complete Response (pCR) rates vary. Studies have shown that patients who achieve pCR after neoadjuvant treatment have a better long-term outcome. Consequently, increasing the rate of pCR became the end point of neoadjuvant trials with the expectation of translation into improved survival. However, for Luminal A subtype patients this is not the case, as this cohort does not respond to chemotherapy. Here we consider why this might be the case and several approaches that could change the paradigm treating this cohort.

https://crimsonpublishers.com/nacs/fulltext/NACS.000546.php

  For More Articles on Journal of Cancer Research Please click on: https://crimsonpublishers.com/nacs/ 

 

 

Comments

Post a Comment

Popular posts from this blog

Recent Advances in the Therapeutic Approaches of Glioblastoma Multiforme_Crimson Publishers

Image
  Recent Advances in the Therapeutic Approaches of Glioblastoma Multiforme by Siddharth Shah in  in Novel Approaches in Cancer Study Abstract Glioblastoma Multiforme (GBM, WHO grade IV) is one of the most aggressive, invasive, and lethal intracranial neoplasms, with a low post-diagnosis survival rate. Standard-of-care treatment regimens involving maximal surgical resection, radiotherapy, and genetic anti-tumor compounds like Temozolomide have only been marginally effective in improving overall survival and quality of life. Cell fusion, autophagy, and other complex biological processes affecting GBM pathophysiology are being studied to improve GBM treatment. This paper therefore focuses on oncolytic virus therapy combined with surgical resection, photodynamic therapy, and novel gene therapy, demonstrating how GBM treatment for patients could result in immediate and authentic tumor cytotoxicity and removal, rather than treatment of recurrent GBM. Standard therapy for GBM,...
Read more

Release of Inorganic Phosphate into the Tumor Environment: Possible Roles of Ecto- Nucleotidases and Ecto-Phosphatases

Abstract Inorganic phosphate (Pi) is essential for several biochemical reaction. Serum Pi is maintained at relatively narrow range concentrations, between 0.7 and 1.55mM. Tumor microenvironment presents a high Pi concentration (1.8±0.2mM Pi) and this could be associated wi the rapid growth in the “Growth Rate Hypothesis”. Several studies have identified high expression of Pi transporters in various tumor tissues. Similarly, ecto-enzymes (like ecto-nucleotidases or ecto- phosphates) act by dephosphorylating phosphosubstrates in the extracellular environment, and its high expression has been observed in various types of cancer. Little is known about the function of these ecto-enzymes on Pi releasing and accumulation in the tumor environment. Therefore, the purpose of this study is to correlate a possible contribution of the Pi release in the tumor microenvironment by ecto-nucleotidases and ecto-phosphatases, concomitant to the regulation of Pi extracellular pool by specific Pi...
Read more

Release of Inorganic Phosphate into the Tumor Environment: Possible Roles of Ecto- Nucleotidases and Ecto-Phosphatases_Crimson Publishers

Image
Release of Inorganic Phosphate into the Tumor Environment: Possible Roles of Ecto- Nucleotidases and Ecto-Phosphatases by Marco Antonio Lacerda-Abreu and José Roberto Meyer- Fernandes in Journal of Cancer Research Crimson Publishers _  Novel Approaches in Cancer Study Inorganic phosphate (Pi) is essential for several biochemical reaction. Serum Pi is maintained at relatively narrow range concentrations, between 0.7 and 1.55mM. Tumor microenvironment presents a high Pi concentration (1.8±0.2mM Pi) and this could be associated wi the rapid growth in the “Growth Rate Hypothesis”. Several studies have identified high expression of Pi transporters in various tumor tissues. Similarly, ecto-enzymes (like ecto-nucleotidases or ecto- phosphates) act by dephosphorylating phosphosubstrates in the extracellular environment, and its high expression has been observed in various types of cancer. Little is known about the function of these ecto-enzymes on Pi releasing and accumulation in the tu...
Read more